Fig. 3

Relative risks and 95 % confidence intervals for risk of adverse clinical events associated with quintile of facility-level proportion of patients with at least two of three CKD-MBD biomarkers out of or above target ranges, using a PTH target range of 150–600 pg/mL. Quintiles of facility-level CKD-MBD composite score were based on proportions of patients at each facility who were out of or above target. “Out of target” was characterized by at least two CKD-MBD laboratory values above or below defined target ranges for PTH, calcium, and phosphate. “Above target” was characterized by at least two CKD-MBD laboratory values above defined target ranges for PTH, calcium, and phosphate. Target ranges for CKD-MBD laboratory values were 150–600 pg/mL for PTH, 8.4–10.2 mg/dL for calcium, and 3.5–5.5 mg/dL for phosphate. Analyses were adjusted for baseline patient demographics, dialysis duration, previous hospitalization, body mass index, comorbid conditions, facility size, and geography. CKD-MBD, chronic kidney disease-mineral bone disorder; CV, cardiovascular; CI confidence interval; PTH, parathyroid hormone